认知障碍患者的语言,视觉空间和动态写作特征 具有β-粉样蛋白沉积的认知障碍患者
Seo Kyung An1, Hyemin Jang2, Hee Jin Kim2
1Department of Speech-Language Pathology and Audiology, Hallym University, Chuncheon, Republic of Korea.
Frontiers in aging neuroscience
|September 27, 2023
概括
认知障碍 (CI) 患者表现出明显的写作缺陷,包括拼写错误和速度减慢,与β-粉样蛋白沉积有关. 这些发现有助于早期CI诊断.
科学领域:
- 神经科学是一个神经科学.
- 认知科学 认知科学
- 语言学的语言学.
背景情况:
- β-粉样蛋白 (Aβ) 沉积是阿尔茨海默病 (AD) 和轻度认知障碍 (MCI) 的关键标志物,在痴呆症之前.
- Aβ沉积与认知和运动障碍有关,包括对写作表现的影响.
研究的目的:
- 在认知障碍 (CI) 和Aβ沉积患者中识别语言,视觉空间和动态写作特征.
- 探索Aβ沉积如何影响患有无记忆性轻度认知障碍 (aMCI) 和阿尔茨海默氏症类型痴呆症 (AD) 的个体的写作.
主要方法:
- 31名有Aβ沉积的aMCI患者,26名AD患者和33名健康对照 (HC) 参与了研究.
- 参与者完成了词语和非词语 (1-4个音节) 发音任务.
- 数字化写作测试分析了语言,视觉空间和动态特征.
主要成果:
- 在aMCI和AD群体中,认知能力下降与不规则的单词语录和字母重写中的错误增加有关.
- 与HC相比,AD组在图形组合中显示了更多的视觉空间错误.
- 在aMCI和AD组中,写作速度明显低于HC组.
结论:
- 患有Aβ沉积的CI患者表现出发言障碍,表明复杂的认知语言运动缺陷.
- 调查结果表明,叶叶的参与影响了拼写和写作.
- 这些写作特征为早期CI诊断提供了宝贵的见解.
更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.0K
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
42.5K
相关概念视频
Alzheimer's Disease: Overview
513
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
513
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
Amyloid Fibrils
5.4K
5.4K
Dementia
131
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
131
